The primary objective of this trial is to investigate safety and tolerability of BI 1356225 in male and female patients with overweight and obesity following oral administration of multiple rising doses per day over 28 days. Secondary objectives are the exploration of pharmacokinetics (PK) of BI 1356225 after multiple oral dosing. Additionally, the relative bioavailability (BA) of midazolam and celecoxib in the presence and absence of BI 1356225 will be evaluated

Inclusion criteria

• Male and female patients, age ≥ 18 and < 70
• Body Mass Index ≥ 27 kg/m2 and < 40 kg/m2 at screening
• Stable body weight (defined as no more than 5% change) within 3 months prior to screening
• further inclusion criteria apply

Exclusion criteria

• Females of childbearing potential
• Clinically relevant concomitant disease per investigator judgment
• Any condition or disease requiring permanent pharmacotherapy during the trial
• Any history of lifetime suicidal behaviour and any suicidal ideation of type 2 - 5 in the Columbia-Suicide Severity Rating Scale (C-SSRS) in the past 12 months
• further exclusion criteria apply

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions: 1. studies in products where Boehringer Ingelheim is not the license holder; 2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; 3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).For more details refer to: http://trials.boehringer-ingelheim.com/